Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Precision Drilling
PDS
5
Teradata Corp
TDC
US Stock MarketDetailed Quotes
INCY Incyte
- 61.930
- +1.380+2.28%
Trading Apr 1 12:09 ET
11.98BMarket Cap412.87P/E (TTM)
62.000High60.280Low550.29KVolume60.530Open60.550Pre Close33.70MTurnover0.34%Turnover Ratio412.87P/E (Static)193.52MShares83.95052wk High3.48P/B9.99BFloat Cap50.35052wk Low--Dividend TTM161.33MShs Float153.150Historical High--Div YieldTTM2.84%Amplitude1.850Historical Low61.241Avg Price1Lot Size
Incyte Stock Forum
Sign in to post a comment
Columns Wall Street Today: DJIA, S&P 500 and Nasdaq Composite All End in the Green on St. Patrick's Day
The Dow Jones Industrial Average, S&P 500 and Nasdaq Composite all ended in the green Monday for St. Patrick's Day, rising for a second straight session as markets continued to partially rebound from their recent tariff-induced sell-off.
The $Dow Jones Industrial Average (.DJI.US)$ led the way higher, gaining 353.45 points (0.9%) to end the day at 41.841.63. The $S&P 500 Index (.SPX.US)$ likewise added 3...
The $Dow Jones Industrial Average (.DJI.US)$ led the way higher, gaining 353.45 points (0.9%) to end the day at 41.841.63. The $S&P 500 Index (.SPX.US)$ likewise added 3...
27
1
5
$Incyte (INCY.US)$
Breakthrough: Dual Phase 3 Trials Prove Povorcitinib's Success in Treating Hidradenitis Suppurativa
Breakthrough: Dual Phase 3 Trials Prove Povorcitinib's Success in Treating Hidradenitis Suppurativa
$Incyte (INCY.US)$
Can Incyte's Opzelura Break Through in Prurigo Nodularis? Phase 3 Data Reveals Critical Insights
Can Incyte's Opzelura Break Through in Prurigo Nodularis? Phase 3 Data Reveals Critical Insights
$Incyte (INCY.US)$
Can Incyte's New Clinical Data Revolutionize Prurigo Nodularis Treatment? AAD 2025 Reveals Answers
Can Incyte's New Clinical Data Revolutionize Prurigo Nodularis Treatment? AAD 2025 Reveals Answers
$Incyte (INCY.US)$
AI Meets Drug Discovery: Inside Incyte's $620M Genesis Deal - Will This Transform Pharma R&D?
AI Meets Drug Discovery: Inside Incyte's $620M Genesis Deal - Will This Transform Pharma R&D?
$Incyte (INCY.US)$ $Agenus (AGEN.US)$ Reuters· 2 mins ago
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.
3
Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...
+2
2
2
🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
8
No comment yet
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Chak : louda tarriff , mad har chod powell cut down the interesr rate